Entrada Therapeutics Reports Second Quarter 2026 Financial Results

-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 --  -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business updates. “With multiple data readouts ahead in 2026, we are well positioned to deliver on important clinical milestones and further demonstrate the potential of our DMD franchise,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.

GlobeNewsWire • Aug 5, 2026

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to a loss of $1.04 per share a year ago.

Zacks Investment Research • Aug 5, 2026

Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 8, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Jun 4, 2026

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study

-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201  -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-45-201. The DMC recommended initiation of the Cohort 2 dose at 10 mg/kg, a dose escalation from 5 mg/kg in Cohort 1.

GlobeNewsWire • Jun 2, 2026

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 18,600 restricted stock units (“RSUs”) to three newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of June 1, 2026. The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Jun 1, 2026

INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC

ATLANTA, May 18, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Entrada Therapeutics, Inc. (“Entrada” or the “Company”) (NASDAQ: TRDA) complied with federal securities laws. On May 7, 2026, Entrada announced ELEVATE-44-201 cohort 1 topline results in its Duchenne muscular dystrophy study. Cohort 1 of the study demonstrated an increase of 2.36% in dystrophin, which fell below analysts' expectations. The price of the Company's stock dropped following this news.

GlobeNewsWire • May 18, 2026

TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, May 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Entrada Therapeutics, Inc. (“Entrada” or “the Company”) (NASDAQ: TRDA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

GlobeNewsWire • May 18, 2026

Entrada Therapeutics, Inc. (TRDA) Q1 2026 Earnings Call Transcript

Entrada Therapeutics, Inc. (TRDA) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 11, 2026

Entrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Entrada Therapeutics, Inc. (NASDAQ: TRDA). The investigation focuses on Entrada's executive officers and whether investor losses may be recovered under federal securities laws.

GlobeNewsWire • May 11, 2026